HK1209046A1 - Manufacture of degarelix - Google Patents

Manufacture of degarelix

Info

Publication number
HK1209046A1
HK1209046A1 HK15109772.8A HK15109772A HK1209046A1 HK 1209046 A1 HK1209046 A1 HK 1209046A1 HK 15109772 A HK15109772 A HK 15109772A HK 1209046 A1 HK1209046 A1 HK 1209046A1
Authority
HK
Hong Kong
Prior art keywords
degarelix
manufacture
Prior art date
Application number
HK15109772.8A
Other languages
English (en)
Chinese (zh)
Inventor
Grgoire Schwach
Anders Nilsson
Boeving Tine Elisabeth Gottschalk
Jon Holbech Rasmussen
Birgitta Mrnstam
Anders Tsirk
Ulf Annby
Jens Fomsgaard
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HK1209046A1 publication Critical patent/HK1209046A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK15109772.8A 2012-06-01 2015-10-07 Manufacture of degarelix HK1209046A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170454 2012-06-01
PCT/EP2013/061264 WO2013178788A2 (en) 2012-06-01 2013-05-31 Manufacture of degarelix

Publications (1)

Publication Number Publication Date
HK1209046A1 true HK1209046A1 (en) 2016-03-24

Family

ID=48539181

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109772.8A HK1209046A1 (en) 2012-06-01 2015-10-07 Manufacture of degarelix

Country Status (19)

Country Link
US (5) US9592266B2 (xx)
EP (1) EP2854831A2 (xx)
JP (1) JP6226966B2 (xx)
KR (1) KR102140982B1 (xx)
CN (2) CN107569456A (xx)
AR (2) AR092840A1 (xx)
AU (1) AU2013269523B2 (xx)
CA (2) CA3228586A1 (xx)
HK (1) HK1209046A1 (xx)
IL (1) IL235856B (xx)
JO (1) JO3586B1 (xx)
MX (1) MX364010B (xx)
MY (1) MY182320A (xx)
NZ (2) NZ701978A (xx)
PH (1) PH12014502682B1 (xx)
RU (1) RU2657444C2 (xx)
SG (1) SG11201407679PA (xx)
TW (1) TWI580443B (xx)
WO (1) WO2013178788A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix
CN107693496A (zh) * 2017-10-23 2018-02-16 天津双硕医药科技有限公司 一种注射用地加瑞克冻干粉针及制备工艺
CN111036078B (zh) * 2018-10-14 2022-04-26 深圳市健元医药科技有限公司 一种GnRH拮抗剂的后处理方法
CN112125956A (zh) * 2019-06-25 2020-12-25 深圳市健元医药科技有限公司 一种地加瑞克的制备方法
CN114938646A (zh) * 2019-12-05 2022-08-23 费森尤斯卡比有限责任公司 分析地加瑞克及其相关产物的方法
CN114460179A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种注射用醋酸地加瑞克体外释放度的测定方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2862341D1 (en) 1977-12-26 1983-11-24 Ihara Chemical Ind Co Process for producing aromatic monocarboxylic acid
DE593491T1 (de) 1991-04-25 1994-11-17 Romano Deghenghi LHRH-Antagonisten.
DK0556034T4 (da) 1992-02-12 2004-11-15 Daikyo Gomu Seiko Kk Et medicinsk instrument
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
WO1999026964A1 (en) 1997-11-20 1999-06-03 Ortho-Mcneil Pharmaceutical, Inc. LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
BR9912275A (pt) * 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
RS20050247A (xx) * 2002-09-27 2007-06-04 Zentaris Gmbh., Oblik za terapijsku primenu aktivnih peptida sa dugotrajnim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
DE602005008247D1 (de) * 2004-06-04 2008-08-28 Camurus Ab Flüssige depotformulierungen
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
ES2589322T3 (es) 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
US8999383B2 (en) * 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
IT1390924B1 (it) 2008-07-31 2011-10-19 Peruffo Metodo di frenatura di attrezzi sportivi, dispositivo di frenatura ed attrezzo sportivo comprendente tale dispositivo di frenatura
RU2515555C2 (ru) * 2009-04-24 2014-05-10 Полипептид Лэборэторис А/С Способ получения дегареликса
BRPI1010874A8 (pt) * 2009-05-01 2018-01-02 Ferring Bv composição para o tratamento de câncer de próstata
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
US20110066386A1 (en) * 2009-09-16 2011-03-17 Chien-Chong Hong Anesthetic sensing optical microfluidic chip system
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
ES2385240B1 (es) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
HUE031113T2 (en) 2010-10-27 2017-06-28 Ferring Bv Procedure for the preparation of Degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
NO2731607T3 (xx) 2011-07-15 2018-03-10
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix

Also Published As

Publication number Publication date
PH12014502682A1 (en) 2015-01-26
US10172906B2 (en) 2019-01-08
US20150141337A1 (en) 2015-05-21
NZ727679A (en) 2018-05-25
NZ701978A (en) 2016-12-23
CN107569456A (zh) 2018-01-12
TW201400143A (zh) 2014-01-01
CN104334182A (zh) 2015-02-04
AU2013269523B2 (en) 2017-09-28
IL235856B (en) 2018-12-31
IL235856A0 (en) 2015-01-29
CA3228586A1 (en) 2013-12-05
RU2014146272A (ru) 2016-07-27
US11510962B2 (en) 2022-11-29
SG11201407679PA (en) 2014-12-30
CA2874927A1 (en) 2013-12-05
AR123619A2 (es) 2022-12-21
US10765721B2 (en) 2020-09-08
EP2854831A2 (en) 2015-04-08
RU2657444C2 (ru) 2018-06-13
AU2013269523A1 (en) 2015-01-15
AR092840A1 (es) 2015-05-06
TWI580443B (zh) 2017-05-01
MX364010B (es) 2019-04-11
JO3586B1 (ar) 2020-07-05
MX2014014662A (es) 2015-02-24
MY182320A (en) 2021-01-19
US11260102B2 (en) 2022-03-01
US20190224271A1 (en) 2019-07-25
WO2013178788A2 (en) 2013-12-05
WO2013178788A3 (en) 2014-02-27
BR112014029495A2 (pt) 2017-06-27
JP2015518866A (ja) 2015-07-06
US20210138024A1 (en) 2021-05-13
US20170319644A1 (en) 2017-11-09
US20210077564A1 (en) 2021-03-18
JP6226966B2 (ja) 2017-11-08
PH12014502682B1 (en) 2015-01-26
KR20150022854A (ko) 2015-03-04
US9592266B2 (en) 2017-03-14
KR102140982B1 (ko) 2020-08-05
CN104334182B (zh) 2017-09-08

Similar Documents

Publication Publication Date Title
HK1212701A1 (zh) 恩雜魯胺製劑
HK1214096A1 (zh) 鞋類物品
SG11201405573WA (en) Production of graphene
GB201301173D0 (en) Object production
ZA201406082B (en) Use of ccr3-inhibitors
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
GB201513279D0 (en) Micro-evolution of microbes
HK1209046A1 (en) Manufacture of degarelix
GB201311220D0 (en) Improved structure of shoe
GB201222832D0 (en) Manufacture of hollow parts
EP2800747A4 (en) POLYMORPHY OF PERAMPANEL
IL236312A0 (en) Preparation of 18f-flucyclobin
EP2881113A4 (en) NEW APPLICATION OF POGOSTONE
IL219244A0 (en) Splitting of user-lists
GB201220155D0 (en) Method of manufacture
HK1214601A1 (zh) 用於製造 -標記物的新型雙-銥-配合物
HK1210225A1 (en) Procedure for the production of tiacumicin
ZA201500488B (en) Manufacture of wheels
EP2892529A4 (en) USES OF (-) - PERHEXILINE
GB201312378D0 (en) Structure of shoe
EP2855401A4 (en) PREPARATION OF BN COMPOUNDS
PL2733011T3 (pl) Osprzęt sieci trakcyjnej
EP2887938A4 (en) PROCESS FOR PREPARING TECOVIRIMAT
IL233446A0 (en) Polymorphic forms of paramphenel
TWM433525U (en) Structure of calorifier